Radiopharm Theranostics (RAD) Emerging Growth Conference 89 summary

Conference overview

• The event is the 89th Emerging Growth Conference, featuring presentations from clinical-stage companies in innovative sectors.

• Radiopharm Theranostics presented its pipeline and strategic direction, focusing on radiopharmaceuticals for high unmet medical needs.

Pipeline and clinical progress

• Five molecules are in clinical stage, with four highlighted: a phase II imaging agent for brain metastasis and three therapeutic agents targeting PD-L1, HER2, and B7-H3.

• The brain metastasis imaging agent (RAD101) is over 50% recruited in phase II, with positive interim data showing 92% concordance with MRI and potential for earlier tumor detection.

• Therapeutic agents are progressing through dose escalation with favorable safety and tumor uptake; B7-H3 monoclonal antibody is ready to dose first patients.

Competitive positioning and partnerships

• The company claims first-in-class status for its imaging and PD-L1 agents, with limited or no direct competition in current clinical stages.

• Strategic partnerships include Lantheus (15% shareholder) and MD Anderson Cancer Center, supporting both development and supply chain security.

• The supply chain for isotopes is diversified across multiple continents, ensuring readiness for late-stage trials and commercialization.